These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 27798488)

  • 1. Challenges in the health economics of familial hypercholesterolemia.
    Norman R; Watts GF; Weintraub W; Gidding SS
    Curr Opin Lipidol; 2016 Dec; 27(6):563-569. PubMed ID: 27798488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Robinson JG
    J Manag Care Pharm; 2013 Mar; 19(2):139-49. PubMed ID: 23461430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States.
    Chen CX; Hay JW
    Int J Cardiol; 2015 Feb; 181():417-24. PubMed ID: 25569270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An economic evaluation alongside a randomized controlled trial evaluating an individually tailored lifestyle intervention compared with usual care in people with familial hypercholesterolemia.
    Broekhuizen K; van Wier MF; Koppes LL; Brug J; van Mechelen W; Bosmans JE; van Poppel MN
    BMC Res Notes; 2015 Jul; 8():317. PubMed ID: 26219281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease.
    Kazi DS; Moran AE; Coxson PG; Penko J; Ollendorf DA; Pearson SD; Tice JA; Guzman D; Bibbins-Domingo K
    JAMA; 2016 Aug; 316(7):743-53. PubMed ID: 27533159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cascade screening based on genetic testing is cost-effective: evidence for the implementation of models of care for familial hypercholesterolemia.
    Ademi Z; Watts GF; Pang J; Sijbrands EJ; van Bockxmeer FM; O'Leary P; Geelhoed E; Liew D
    J Clin Lipidol; 2014; 8(4):390-400. PubMed ID: 25110220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands.
    Wonderling D; Umans-Eckenhausen MA; Marks D; Defesche JC; Kastelein JJ; Thorogood M
    Semin Vasc Med; 2004 Feb; 4(1):97-104. PubMed ID: 15199439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of people with heterozygous familial hypercholesterolemia.
    Haase A; Goldberg AC
    Curr Opin Lipidol; 2012 Aug; 23(4):282-9. PubMed ID: 22801386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New decision-making processes for the pricing of health technologies in Japan: The FY 2016/2017 pilot phase for the introduction of economic evaluations.
    Shiroiwa T; Fukuda T; Ikeda S; Takura T
    Health Policy; 2017 Aug; 121(8):836-841. PubMed ID: 28687183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early initiation of statin treatment in children with familial hypercholesterolaemia.
    Braamskamp MJ; Hutten BA; Wiegman A
    Curr Opin Lipidol; 2015 Jun; 26(3):236-9. PubMed ID: 25943840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Familial hypercholesterolaemia: a review with emphasis on evidence for treatment, new models of care and health economic evaluations.
    Watts GF; Juniper A; van Bockxmeer F; Ademi Z; Liew D; O'Leary P
    Int J Evid Based Healthc; 2012 Sep; 10(3):211-21. PubMed ID: 22925618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiac computed tomography imaging in familial hypercholesterolaemia: implications for therapy and clinical trials.
    Sijbrands EJ; Nieman K; Budoff MJ;
    Curr Opin Lipidol; 2015 Dec; 26(6):586-92. PubMed ID: 26780011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future issues, public policy, and public awareness of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia.
    Goldberg AC; Robinson JG; Cromwell WC; Ross JL; Ziajka PE
    J Clin Lipidol; 2011 Jun; 5(3 Suppl):S46-51. PubMed ID: 21600529
    [No Abstract]   [Full Text] [Related]  

  • 15. Familial hypercholesterolemia in children and adolescents.
    McCrindle BW
    Curr Opin Lipidol; 2012 Dec; 23(6):525-31. PubMed ID: 22914663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic reviews of economic evaluations: utility or futility?
    Anderson R
    Health Econ; 2010 Mar; 19(3):350-64. PubMed ID: 19378354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying familial hypercholesterolemia in acute coronary syndrome.
    Gencer B; Nanchen D
    Curr Opin Lipidol; 2016 Aug; 27(4):375-81. PubMed ID: 27092769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term survival of childhood coronary artery disease in a patient severely affected with familial hypercholesterolemia.
    Sibley C; McGann S; Stone NJ
    Am J Cardiol; 2004 Sep; 94(5):699-700. PubMed ID: 15342318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of registries and genetic databases in familial hypercholesterolemia.
    Kindt I; Mata P; Knowles JW
    Curr Opin Lipidol; 2017 Apr; 28(2):152-160. PubMed ID: 28169870
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.